2022
DOI: 10.1016/j.msard.2021.103392
|View full text |Cite
|
Sign up to set email alerts
|

Percutaneous posterior tibial nerve stimulation (PTNS) for lower urinary tract symptoms (LUTSs) treatment in patients with multiple sclerosis (MS): A systematic review and meta-analysis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
11
0
1

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 10 publications
(13 citation statements)
references
References 22 publications
0
11
0
1
Order By: Relevance
“…Screening the titles and abstracts, left us with 76 studies which were selected for full‐text screening. Finally, 20 SRs met all the inclusion criteria and entered the study 16–35 . The PRISMA flow diagram of the literature search and results is shown in Figure 1.…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…Screening the titles and abstracts, left us with 76 studies which were selected for full‐text screening. Finally, 20 SRs met all the inclusion criteria and entered the study 16–35 . The PRISMA flow diagram of the literature search and results is shown in Figure 1.…”
Section: Resultsmentioning
confidence: 99%
“…From a total of 20 SRs, 13 of them conducted meta‐analysis 16,17,19,20,23,24,27,29,31–35 . China was the leading origin of publication with five studies 16,31–34 .…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…6 Currently, specific and validated questionnaires have been widely used in neurourology, focusing on lower urinary tract symptoms (LUTS) and on their impact on QoL. 7 Percutaneous tibial nerve stimulation (PTNS) is an effective neuromodulatory technique widely used as a third-line 8 treatment for MS patients experiencing LUTS; [9][10][11][12][13] however, to our knowledge, controlled studies are still not available. The aim of this study was to evaluate the efficacy of PTNS in the treatment of MS patients with NDO unresponsive to pharmacological and behavioural therapies.…”
Section: Introductionmentioning
confidence: 99%